"N" - Chester Clinic:

Fuji_email blast_f-melt_feb16.2011.indd

F-MELT series, Issue2, February 2011 Formulating Taste Masked and High Quality ODT of Poorly Water Soluble Drugs In this paper, we present case studies with taste masking technology and application of wet granulation technologies to develop ODTs of Loratadine, a water insoluble drug, and Famotidine, a slightly water


Dietas y control del peso 33dossier entrevista artículos Presentación de los puntos Dr. Quiles Izquierdo Dietas milagro o cómo clave del nuevo consenso Jefe de la Unidad no se debe adelgazar de Educación para la Salud Dirección General de Investigación y Salud Pública Microbiota intestinal


AnnuAl BoArd updAte STATE OF NEVADA BOARD OF VETERINARY MEDICAL EXAMINERS From The President Richard Simmonds, DVM, MS Richard Simmonds, DVM, MS, ACLAM I am honored to have been selected by my is regulatory in nature and charged with enforcing colleagues on the Nevada Board of Veterinary the Nevada Practice Act and the Association is a Craig Schank, DVM

Powerpoint presentation

Renal Care in the Community Lynette Knuth. RN, BSc, PG cert Crit care, PGDip NS. 2014 Masters candidate Chronic Kidney Disease – Stage 4 Nurse Specialist - 0.5 fte Clinical Nurse Specialist – 0.1 fte Dialysis Nurse (PD and HD) – 0.3 fte 30 May 2014 • Past, present and future of the Anaemia protocol • CKD stage 4: management • Advanced care planning: end of life care


Krieg aus der Sicht der Opfer Photographien von Jean Mohr Eine Ausstellung des Musée de l'Elysée, Lausanne, in Zusammenarbeit mit dem Eidgenössischen Departement für auswärtige Angelegenheitenvom 23.08. – 26.10.2014 im Landesmuseum Zürich della guerraFotografie di Jean Mohr Una mostra organizzata dal Musée de l'Elysée, Losanna, in collaborazione con il Dipartimento federale degli affari esteridal 23.08. – 26.10.2014 al Landesmuseum Zürich


Quarterly Newsletter of National Programme for Control of Blindness Theme of the Issue: New Initiatives of National Programme for Control of Blindness Volume: 1 From the Editor's Desk New Initiatives of National Programme for Control of 1. Editorial: New Initiatives of National Programme for Control of Blindness:

12020_2007_14_31_1-web 72.8

Endocr (2007) 31:72–81 Phytosterol Pygeum africanum regulates prostate cancerin vitro and in vivo Nader S. Shenouda Æ Mary S. Sakla Æ Leslie G. Newton ÆCynthia Besch-Williford Æ Norman M. Greenberg ÆRuth S. MacDonald Æ Dennis B. Lubahn Published online: 5 May 2007 Humana Press Inc. 2007 benign prostatic hypertrophy (BPH). More recently in the Prostate cancer is an important public health

Growing american ginseng in ohio: an introduction

Agriculture and Natural Resources Growing American Ginseng in Ohio: Chip Carroll Dave Apsley Rural Action Sustainable Forestry Natural Resources Specialist and Appalachian Forest Resources Center Ohio State University Extension American ginseng (Panax quinquefolium), one of the world's most valued plants, is found throughout the


LGL 2007 Sustainability Report People Results Growth Welcome to this Report "We have progressed from being a one site This report details the advances operation to being a world class producer with a made by Lihir Gold Limited (LGL) in 2007 to operate as an ethical, global vision for the future. We have also matched sustainable business. In it, we

Komplementärmedizin – warum wir couchepin überleben

Warum wir Couchepin überleben Dr. med. Joerg Fritschi, CH-4148 Pfeffingen • Geburtsdatum 31.10.1955• Staatsexamen 1981• FMH Innere Medizin 1989• Praxis: Im Noll 38, 4148 Pfeffingen seit 1989• ASA-TCM 1999• Vize-Präsident SGIM 2001-2002• FACP 2002 Dr. med. Joerg Fritschi, CH-4148 Pfeffingen


Direction Régionale de la Concurrence, Lignes Direccte de la Consommation,du Travail et de l'Emploi de Basse-Normandie Publication trimestrielle de la Direction Régionale des Entreprises, de la Concurrence, de la Consommation, Conjoncture du Travail et de l'Emploi de Basse-Nor Le Bâtiment et la construction durable – Plan Bâtiment Grenelle Le Bâtiment en Basse-Normandie, ce sont 4 748 entreprises

Chandrakanth are md, mba

Chandrakanth Are Curriculum Vitae Chandrakanth Are MD, MBA CURRICULUM VITAE Chandrakanth Are, MD, MBA, FRCS, FACS FATHER'S NAME: Dasaratha Naidu Are ADDRESS: University of Nebraska Medical Center Department of Surgery Division of Surgical Oncology 986345 Nebraska Medical Center Omaha, Nebraska 68198-4030

Microsoft word - legionala urinary antigen eia new.doc

An enzyme immunoassay (EIA) based system for the qualitative detection of Legionella pneumophila serogroup 1 antigen (L. pneumophila serogroup 1 antigen) in human urine as an adjunct to culture for the presumptive diagnosis of past or current Legionnaires' Disease. The majority of Legionnaires' Disease is caused by Legionella pneumophila serogroup 1 and is characterized as an acute febrile respiratory illness that

2012-07-19-final report pigs_nf jul 29

CODE OF PRACTICE FOR THE CARE & HANDLING OF PIGS: REVIEW OF SCIENTIFIC RESEARCH ON PRIORITY ISSUES JULY 2012 Pig Code of Practice Scientists' Committee Harold W. Gonyou B.Sc.(Agr), M.Sc., Ph.D. (Chair) Research Scientist Prairie Swine Centre and Adjunct Professor, University of Saskatchewan Nicolas Devillers Ph.D

Microsoft word - februarypaperbcco gmmmg nts summary paper

North Manchester CCG Board Meeting – 11 February 2015 Dr Martin Whiting Paper prepared by: Dr Martin Whiting Dr Martin Whiting Sub-Committee consideration Chief Clinical Officer's Report Background papers and links to priorities/objectives: To provide an update to the board on strategic Purpose of the paper: developments within Greater Manchester.

Microsoft word - ncda field service volunteer revised curriculum

SUBSTANCE ABUSE TRAINING MANUAL Information Guide for Peer Educators NCDA Field Department FIELD SERVICES DEPARTMENT Table of Contents Contents Training Objectives: . 4 Course Outline: . 5 The National Council on Drug Abuse- Structure, Objectives, and Operations. 5  Categories of drugs . 5 Commonly abused substances – alcohol, tobacco, marijuana, crack cocaine, amphetamines, steroids. 5

Adventure works 2008 sales proposal

The Florida Journey Adapting FIMR to Address Maternal Mortality Karen R. Coon, ARNP, MSN Florida Department of Health Division of Community Health Promotion Infant, Maternal & Reproductive Health "You can't really understand another person's experience until you've walked a mile in their shoes." . The Florida Journey: Adapting FIMR to Address Maternal Mortality

Cutaneous radiation injury: fact sheet for physicians

FACT SHEET Cutaneous Radiation Injury: Fact Sheet for Physicians Injury to the skin and underlying tissues from acute exposure to a large external dose of radiation is referred to as cutaneous radiation injury (CRI). Acute radiation syndrome (ARS)ill usually be accompanied by some skin damage; however, CRI can occur without symptoms of ARS. This is especially


Core SPC Fluanxol® Depot 20 mg-ml, 100 mg-ml 200 mg-ml Summary of product characteristics NAME OF THE MEDICINAL PRODUCT Fluanxol Depot 20 mg/ml solution for injectionFluanxol Depot 100 mg/ml solution for injectionFluanxol Depot 200 mg/ml solution for injection QUALITATIVE AND QUANTITATIVE COMPOSITION Flupentixol decanoate 20 mg/ml.Flupentixol decanoate 100 mg/ml.Flupentixol decanoate 200 mg/ml.


Economics of Lithium Technology for ASR Control vs. AlternativesBy Claudio Manissero, Sales and Marketing Manager, FMC Corporation, Lithium Division Randall Stewart, Lithium Technology Manager, The Euclid Chemical Company Concrete durability, and more specifically Alkali Silica Reac- tivity (ASR) is fast becoming an item of great concern toowners following research conducted under the StrategicHighway Research Program (SHRP) and more recently


Endothelial Dysfunction in Obese Children Biochemistry Section Namrata ChhaBra, SahiBa KuKreja, Sahil ChhaBra, Sarah ChhaBra, KaviSh rameSSur that link obesity to endothelial dysfunction. Endothelial The magnitude of lifetime risk of cardiovascular disease dysfunction is a reversible disorder, pharmacological (CVD) has radically increased along with the high and non pharmacological interventions can reverse the

Powerpoint presentation

Council on Aspirin Health and Prevention National Commission on Prevention Priorities: In 2007, the Partnership for Prevention-convened National Commission on Prevention Priorities published a new study ranking those community preventive services that provide the greatest impact and are the most cost-effective. The research concluded that utilization rates remain low for many preventive services that are very


Naturetrek Tour Report 22 - 29 April 2016 Hermann's Tortoise Report and images by Ian Nicholson & Martin Beaton T: +44 (0)1962 733051 Tour Report Tour participants: Ian Nicholson & Martin Beaton (leader) with 14 Naturetrek clients This holiday looked at all aspects of wildlife on the attractive island of Menorca, focussing mainly on birds and plants, but also including butterflies and dragonflies, although it was slightly early in the season for the latter two groups. The weather was somewhat mixed, with a couple of chilly mornings, but also some sunny afternoons, and during the course of the week we saw a good variety of wildlife, as well as touching briefly on some of the history of the island.



Microsoft word - v20 novolog pi text (9mar2013).doc

HIGHLIGHTS OF PRESCRIBING INFORMATION  Insulin, particularly when given intravenously or in settings of poor These highlights do not include all the information needed to use NovoLog glycemic control, can cause hypokalemia. Use caution in patients safely and effectively. See full prescribing information for NovoLog. predisposed to hypokalemia (5.3).




NAME OF THE MEDICINAL PRODUCT: Aprotinin 10,000 KIU/ML Injection BP. PRESENTATION: Each 50ml 1 vial of 50 mL contains aprotinin concentrated solution, corresponding to 500,000 KIU (Kallikrein Inhibitor Units) in sterile 0.9% sodium chloride solution. INDICATIONS: Aprotinin is indicated for prophylactic use to reduce blood loss and blood transfusion in adult patients who are at high risk of major blood loss undergoing isolated cardiopulmonary bypass graft surgery (i.e. coronary artery bypass graft surgery that is not combined with other cardiovascular surgery). Aprotinin should only be used after careful consideration of the benefits and risks, and the consideration that alternative treatments are available. POSOLOGY AND METHOD OF ADMINISTRATION: Posology: An appropriate aprotinin-specific IgG antibody test may be considered before administration of aprotinin. Adult: Owing to the risk of allergic/anaphylactic reactions, a 1 ml (10,000 KIU) test dose should be administered to all patients at least 10 minutes prior to the remainder of the dose. After the uneventful administration of the 1 ml test dose, the therapeutic dose may be given. A H1-antagonist and a H2-antagonist may be administered 15 minutes prior to the test dose of aprotinin. In any case standard emergency treatments for anaphylactic and allergic reactions should be readily available (see section 4.4). A loading dose of 1 - 2 million KIU is administered as a slow intravenous injection or infusion over 20 - 30 minutes after induction of anaesthesia and prior to sternotomy. A further 1 - 2 million KIU should be added to the pump prime of the heart-lung machine. To avoid physical incompatibility of aprotinin and heparin when adding to the pump prime solution, each agent must be added during recirculation of the pump prime to assure adequate dilution prior to admixture with the other component. The initial bolus infusion is followed by the administration of a continuous infusion of 250,000 - 500,000 KIU per hour until the end of the operation. In general, the total amount of aprotinin administered per treatment course should not exceed 7 million KIU. Paediatric population - The safety and efficacy in children below 18 years of age have not been established. Refer to Summary of Product Characteristics for use in other specific patient populations. Aprotinin should be infused using a central venous catheter. The same lumen should not be used for the administration of any other medicinal product. When using a multi-lumen central catheter a separate catheter is not required. Aprotinin must be given only to patients in the supine position and must be given slowly (maximum 5 - 10 ml/min) as an intravenous injection or a short infusion. CONTRAINDICATIONS: Hypersensitivity to the active substance or any of the excipients. Patients with a positive aprotinin specific IgG antibody test. If no such test is possible prior to treatment, administration of aprotinin to patients with a suspected previous exposure including in fibrin sealant products during the last 12 months is contraindicated. SPECIAL WARNINGS AND PRECAUTIONS FOR USE: Aprotinin should not be used when CABG surgery is combined with another cardiovascular surgery because the benefit risk balance of aprotinin in other cardiovascular procedures has not been established. Laboratory monitoring of anticoagulation during cardiopulmonary bypass: Aprotinin is not a heparin-sparing agent and it is important that adequate anticoagulation with heparin be maintained during aprotinin-therapy. Elevations in the partial thromboplastin time (PTT) and celite. Activated Clotting Time (Celite ACT) are expected in aprotinin-treated patients during surgery, and in the hours after surgery. Therefore, the partial thromboplastin time (PTT) should not be used to maintain adequate anticoagulation with heparin. In patients undergoing cardiopulmonary bypass with aprotinin therapy, one of three methods is recommended to maintain adequate anticoagulation: Activated Clotting Time (ACT), Fixed Heparin Dosing, or Heparin Titration (see below). If activated clotting time (ACT) is used to maintain adequate anticoagulation, a minimal celite-ACT of 750 seconds or kaolin-ACT of 480 seconds, independent of the effects of haemodilution and hypothermia, is recommended in the presence of aprotinin. Important: aprotinin is not a heparin-sparing agent. Graft Conservation: Blood drawn from the aprotinin central infusion line should not be used for graft preservation. Re-exposure to aprotinin: Administration of aprotinin, especially to patients who have received

Ug symposium program-2012

6th Annual North Park University Undergraduate Research Symposium Tuesday, April 17, 2012 North Park University Chicago, Illinois Dr. Rachel Schmale Session 1 John-Tyler Carlson Session 2 Closing Remarks 5:20–5:25 pm Dr. Matthew Schau Following the symposium: Discussion and dinner (served at 5:45 pm) for presenters and advisors in Olssson Lounge, Seminary Building.

Prevention of adhesions during laparoscopic surgery in mice with crystalloids

November 2002, Vol. 9, No. 4 The Journal of the American Association of Gynecologic Laparoscopists Prevention of Adhesions with Crystalloidsduring Laparoscopic Surgery in Mice Osama Ali Elkelani, M.D., Carlos Roger Molinas, M.D., Ospan Mynbaev, M.D., Ph.D., and Philippe Robert Koninckx, M.D., Ph.D. Study Objective. To evaluate the effect of saline and Ringer's lactate solutions in preventing adhesions during lapa-roscopic surgery in mice.Design. Prospective, randomized trial (Canadian Task Force classification I).Setting. Academic research center.Subjects. Ninety-two female Naval Medical Research Institute mice.Intervention. Adhesions were induced laparoscopically by opposing bipolar lesions in the uterine horns and pelvicsidewalls, and saline or Ringer's lactate solution was added at different times during the procedure.Measurements and Main Results. Adhesions were scored quantitatively and qualitatively for extent, type, and tenac-ity after 7 days under microscopic vision during laparotomy. After 45 minutes of pneumoperitoneum, neither solu-tion reduced adhesion formation, but when added immediately after surgery they did (p = 0.002). Coagulationwas not significantly different with addition of either solution immediately after coagulation. In the third experi-ment the presence of fluid during pneumoperitoneum decreased adhesion formation (p = 0.0001) but Ringer'slactate was more effective than saline (p = 0.0005).Conclusion. Crystalloids reduced CO2 pneumoperitoneum-enhanced adhesion formation in a laparoscopic mouse

National audit of seizure management in hospitals

National Audit of Seizure Management in Hospitals St. Elsewhere's Hospital Clinical Report, April 2014 2013 NASH Audit Report Prepared by: Professor Mike Pearson, Professor of Clinical Evaluation Professor Tony Marson, Professor of Neurology Pete Dixon, NASH Study Coordinator Karen Scott, NASH Study Administrator The National Audit of Seizure Management in Hospitals is funded by Eisai Ltd, UCB Pharma, Viropharma and University of Liverpool.

Certified registered nurse anesthetist burnout related to moral distress: a replication study

Southern California CSU DNP Consortium California State University, Fullerton California State University, Long Beach California State University, Los Angeles POST BURN PRURITUS RELIEF PROTOCOL A DOCTORAL PROJECT Submitted in Partial Fulfillment of the Requirements For the degree of DOCTOR OF NURSING PRACTICE Doctoral Project Committee Approval: Gail Washington, DNS, RN, PHN, Project Chair